A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

Here’s what you can do to help boost your brain’s neurogenesis.

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

Genetic changes are a significant cause of infertility, impacting over 15% of the global population. TLE6, a major protein ...

Infertility is a major global challenge associated with physiological and psychological impact. Genetic mutations that affect ...

CRISPR screening libraries are collections of carefully designed single-guide RNAs (sgRNAs) that allow researchers to ...

Crispant analysis in zebrafish serves as a powerful tool for the rapid functional screening of genes implicated in bone fragility disorders, like osteogenesis imperfecta and osteoporosis.

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Gene editing involves precise changes in DNA sequences using enzymes, revolutionizing medical, agricultural, and research ...

popularly called knockout or banger, inside the church on New Year’s Eve. PUNCH Metro gathered that the event left the boy, identified simply as Joseph, dead and others injured. A source who ...